Akari Therapeutics (NASDAQ:AKTX) Now Covered by Analysts at StockNews.com
StockNews.com began coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Rating) in a research report released on Saturday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Akari Therapeutics Stock Performance NASDAQ AKTX opened at $0.19 on Friday. The stock has a 50-day simple moving average of $0.26 and a two-hundred […]